首页> 美国卫生研究院文献>other >Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Findings Based on North Central Cancer Treatment Group (NCCTG) Trials

【2h】

Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Findings Based on North Central Cancer Treatment Group (NCCTG) Trials

机译：肿瘤反应和无进展生存作为广泛阶段的小细胞肺癌整体存活的潜在替代终点（ES-SCLC）：基于北中央癌症治疗组（NCCTG）试验的研究结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeWe investigated the putative surrogate endpoints (PSEs) of best response (BR), complete response (CR), confirmed response (CoR), and progression-free survival (PFS) for associations with Overall Survival (OS), and as possible surrogate endpoints for OS.

著录项

期刊名称 other
作者
Nathan R. Foster; Yingwei Qi; Qian Shi; James E. Krook; John W. Kugler; James R. Jett; Julian R. Molina; Steven E. Schild; Alex A. Adjei; Sumithra J. Mandrekar;
展开▼
作者单位

展开▼
年(卷),期 -1(117),6
年度 -1
页码 1262–1271
总页数 16
原文格式 PDF
正文语种
中图分类
关键词
extensive-stage small cell lung cancer surrogate endpoints pooled analysis progression-free survival tumor response;

机译：广泛期小细胞肺癌;替代终点;汇总分析;无进展生存期;肿瘤反应;

相似文献

外文文献
中文文献
专利

1. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials [J] . Wang Xiaofei, Wang Xiaoyi, Hodgson Lydia, The oncologist . 2017,第2期

机译：作为恶性间皮瘤整体存活的替代终点的无进展生存的验证：癌症和白血病组B和北中央癌症治疗组（联盟）试验分析
2. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer [J] . FosterN.R., QiY., ShiQ., Cancer: A Journal of the American Cancer Society . 2011,第6期

机译：肿瘤反应和无进展生存是广泛期小细胞肺癌总体生存的潜在替代终点
3. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer [J] . Nathan R. Foster MS, Yingwei Qi MD MS, Qian Shi PhD, Cancer . 2011,第6期

机译：肿瘤反应和无进展生存是广泛期小细胞肺癌总体生存的潜在替代终点
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Treating Very Large Non-Small Cell Lung Cancers: A Survival Analysis using National Cancer Databases [D] . Moreno, Amy Catherine 2014

机译：治疗非常大的非小细胞肺癌：使用国家癌症数据库的生存分析
6. Multi-Trial Evaluation of Progression-Free Survival (PFS) as a Surrogate Endpoint for Overall Survival (OS) in First-Line Extensive-Stage Small Cell Lung Cancer (ES-SCLC) [O] . Nathan R. Foster, Lindsay A. Renfro, Steven E. Schild, -1

机译：无进展生存期（PFS）作为一线广泛期小细胞肺癌（ES-SCLC）总生存期（OS）的替代终点的多重试验评估
7. Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review. [O] . Katsuyuki Hotta, Yuka Kato, Natasha Leighl, 2015

机译：系统评价在分子选择的晚期非小细胞肺癌患者中评估靶向药物的3期试验中，无进展生存作为潜在替代指标的益处的大小。

Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Findings Based on North Central Cancer Treatment Group (NCCTG) Trials

摘要

著录项

相似文献

相关主题

期刊订阅